1988
DOI: 10.1097/00007890-198812000-00007
|View full text |Cite
|
Sign up to set email alerts
|

The Mechanism of Discordant Xenograft Rejection

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

3
86
0

Year Published

1991
1991
2012
2012

Publication Types

Select...
7
3

Relationship

1
9

Authors

Journals

citations
Cited by 229 publications
(89 citation statements)
references
References 0 publications
3
86
0
Order By: Relevance
“…Third, while the pathogenesis of acute vascular rejection is generally thought to reflect activation of endothelial cells in the transplant (6,17,18), the course of hyperacute rejection proceeds too rapidly to allow the most significant effects of endothelial cell activation to be manifest. Fourth, acute vascular rejection develops when the complement system of the recipient is inactivated (6, 7), a condition that invariably precludes the development of hyperacute rejection (19,20).…”
Section: Introductionmentioning
confidence: 99%
“…Third, while the pathogenesis of acute vascular rejection is generally thought to reflect activation of endothelial cells in the transplant (6,17,18), the course of hyperacute rejection proceeds too rapidly to allow the most significant effects of endothelial cell activation to be manifest. Fourth, acute vascular rejection develops when the complement system of the recipient is inactivated (6, 7), a condition that invariably precludes the development of hyperacute rejection (19,20).…”
Section: Introductionmentioning
confidence: 99%
“…It plays an important role in host defence, inflammation, and allergic reactions (Sundsmo andFair, 1983: Kuby, 1994). The activation of complement releases C3 a , C4 a , and C5 a , but they result in organ transplant rejection (Miyagawa et al, 1988;Dimond, 1995), asthma, allergy, atopys dermatitis (Groggel et al, 1983;Rother et al, 1985;Strunk et al, 1988;Alexandef et al, 1988;McGeer and McGeer, 1995), arthritis, systemic lupus erythematosus and ARDS (Carson, 1985;Murry et al, 1988;Zvaifler, 1989). For the prevention and treatment of these diseases, anticomplementary polysaccharides, for example, lipopolysaccharide (Gewurz et al, 1968;Marcus et al, 1971), 6-* Author to whom correspondence should be addressed.…”
Section: Introductionmentioning
confidence: 99%
“…It is primarily mediated by activation of the human complement cascade following the interaction of ␣-Gal epitopes on pig cells and anti-␣-Gal xenoreactive antibodies naturally present in humans and in Old World primate serum (1,15,41). Due to its nonspecific nature, the complement system is regulated by a family of complement-regulatory proteins (CRPs) thought to function in a species-specific manner (23). The suggestion that human CRPs (hCRP) expressed on pig organs may prevent HAR has led to the development of pigs transgenic for hCRPs, including decay-accelerating factor (DAF; CD55), membrane cofactor protein (CD46), and membrane inhibitor of reactive lysis (CD59) (3,14,18,54).…”
mentioning
confidence: 99%